Sign up to save your podcasts
Or
Share CAR T-cell therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CAR T-cell therapy
Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Oncology in conversation with
View all
Global News Podcast
7,695 Listeners
NEJM This Week
321 Listeners
The Daily
112,934 Listeners
OncoPharm
187 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
anything goes with emma chamberlain
62,566 Listeners
The Uromigos
57 Listeners
The Lancet Voice
20 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
EHA Unplugged
1 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
What Did You Do Yesterday? with Max Rushden & David O'Doherty
222 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners